GTHX - G1 Therapeutics, Inc.
IEX Last Trade
7.155
7.155 100.000%
Share volume: 0
Last Updated: Wed 18 Sep 2024 11:18:55 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
Fundamental analysis
25%
Profitability
25%
Dept financing
3%
Liquidity
50%
Performance
25%
Performance
5 Days
0 0%
1 Month
0 0%
3 Months
0 0%
6 Months
225.00%
1 Year
139.93%
2 Year
30.47%
Key data
Stock price
$7.16
DAY RANGE
N/A - N/A
52 WEEK RANGE
$2.23 - $7.19
52 WEEK CHANGE
$129.17
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Jack Bailey
Region: US
Website: g1therapeutics.com
Employees: 170
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: g1therapeutics.com
Employees: 170
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
G1 Therapeutics, Inc. engages in the discovery, development, and commercialization of small molecule therapeutics. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; and rintodestrant, an oral selective estrogen receptor degrader.
Recent news